## (19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 9 September 2005 (09.09.2005)

**PCT** 

## (10) International Publication Number WO 2005/082096 A2

(51) International Patent Classification: Not classified

(21) International Application Number:

PCT/US2005/006421

(22) International Filing Date: 23 February 2005 (23.02.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/547,591

24 February 2004 (24.02.2004) Us

(71) Applicant (for all designated States except US): ALLER-GAN, INC. [US/US]; 2525 Dupont Drive, Irvine, CA 92612 (US).

(72) Inventors; and


(75) Inventors/Applicants (for US only): FERNAN-DEZ-SALAS, Ester [ES/US]; 1710 Rocky Road, Fullerton, CA 92831 (US). GARY, Patton, E. [US/US]; 2021 N. Beverly Place, #137, Long Beach, CA 90815

(US). AOKI, Kei, Roger [US/US]; 2 Ginger Lily Court, Coto de Caza, CA 92679 (US).

- (74) Agent: STATHAKIS, Dean, G.; c/o Allergan, Inc., 2525 Dupont Drive, Irvine, CA 92612 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: BOTULINUM TOXIN SCREENING ASSAYS



(57) Abstract: Methods for detecting BoNT/A activity in a sample, methods for screening molecules able to compete with BoNT/A receptor binding, methods for reducing BoNT/A activity in a human and methods of marketing a neurotoxin capable of selectively binding to FGFR3 to a governmental or regional regulatory authority.

## WO 2005/082096 A2



## Published:

 without international search report and to be republished upon receipt of that report For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.